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Abstract In recent years, considerable attention focuses
on making sustained release dosage forms also containing
solid dispersions. The objective of this study is evaluation
of imatinib base (IMA) solid dispersion physicochemical
properties which can be useful to controlled release solid
dosage formation. The solid dispersions were obtained by
kneading method, containing of 10–90% w/w Pluronic
F127 (PLU). Drug dissolution test was determined by
rotating-disc system method in 0.1 M hydrochloric acid
(pH 1.2) and phosphate buffer (pH 6.8). XRD, DSC, FTIR,
and SEM observations were performed to evaluate the
physical characteristics of solid dispersions. These studies
showed that there was no chemical interaction of the IMA
with PLU in the solid state and revealed that IMA and PLU
form a simple eutectic phase diagram. Our research has
shown that the dynamics of the release of imatinib base
from solid dispersions with Pluronic F127 depends on the
pH of dissolution medium. At pH 1.2, the presence of
polymer in solid dispersion causes delaying of drug release
due to formation a viscous gel layer, whereas at pH 6.8
significant enhancement of the drug dissolution rate from
solid dispersions has been observed compared to pure
IMA. The highest improvement was observed in solid
dispersions containing 20 and 30% w/w polymer. The
present investigation confirmed that the hydrophilic poly-
mer Pluronic F127 could be applied as a suitable matrix to
design modified release formulations of imatinib base.
Keywords Imatinib base  Pluronic F127  Solid
dispersion  DSC  Phase diagram  IDR  XRPD
Introduction
The rate or extent of dissolution of drug from any solid
dosage form is a rate-limiting step in the poor process
of water-soluble drug absorption. Imatinib N-(4-methyl-3-
((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-
((4methylpiperazin-1-yl)methyl)benzamide (see Fig. 1) is
a first-generation antitumor protein tyrosine kinase inhi-
bitor and antileucemia cytostatic agent, which shows low,
pH-dependent solubility. In aqueous media, imatinib base
is characterized by poor solubility (0.01 mg mL-1) [1].
However, the mesylate salt of imatinib, which exists as a
polymorph with two principal forms, [2, 3] is very soluble
in media at pH values B5.5, but in neutral and alkaline
aqueous buffers is poorly soluble or insoluble [4]. There-
fore, imatinib mesylate belongs to Class 2 of Biopharma-
ceutical Classification System (BCS) with a solubility of
1 mg mL-1 determined at pH 7.4 [4]. After oral adminis-
tration, especially of the conventional dosage forms, ima-
tinib mesylate is not absorbed to the same extent, when it
passes the upper small intestine, where its absorption is the
maximum. Recommended dosage form for this substance
should be form, which continuously releases the drug in the
stomach before reached its the absorption window, thus
ensuring optimal bioavailability of substance [5]. Hence
there is a great interest in the development of new imatinib
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formulations, which could maintain optimum therapeutic
plasma drug concentrations to avoid inter-patient vari-
ability and side effects. The usual oral recommended dose
of imatinib for humans is between 50 and about
1600 mg day-1, in two or four doses. The formulations
provide rapid dissolution of the active ingredient that in
turn results in its rapid increase in blood plasma levels
above the therapeutic steady state levels, immediately after
administration followed by approaching a decrease in
blood plasma levels up to subtherapeutic plasma levels
after about 12 h following oral administration, thus
requiring additional dosing [5]. Vinod et al. [5] obtained
gastroretentive floating tablets, which showed good
floatation during the period of imatinib mesylate release.
Ravindran et al. have developed single-unit-controlled
release imatinib mesylate oral dosage form which can
retain the drug in the stomach for prolonged duration by
mucoadhesive nature of the dosage form and to achieve
therapeutic levels over an extended period of 12 h for the
treatment of chronic myelogenous leucemia and gastroin-
testinal stromal tumour [6].
Solid dispersions (SDs) are generally used in order to
improve the dissolution rate and the bioavailability of poorly
soluble active pharmaceutical ingredients (APIs). In the
literature can be found also report on the application of solid
dispersions for the controlled release of drugs [7]. Patil et al.
[8] have used the SDs containing a polymer blend, such as
hydroxypropylcellulose and ethylcellulose that allowed
possible to precisely control the rate of release of water-
soluble drug. The improvement of drug dissolution profile
from solid dispersions is observed, when the ratio of carriers
in solid dispersions increased, and the drug was dispersed
better and the drug crystallinity decreased. In these solid
dispersions, the main release mechanism is drug-controlled
release. Other researchers observed the decrease in drug
dissolution rate when the ratio of carrier in solid dispersions
was increased. This can be explained by the carrier-
controlled mechanism in which the gel or concentrated
carrier layer is formed and acts as a diffusion barrier to delay
drug release. Therefore, it is important identify of drug
release mechanism from solid dispersions. In carrier-con-
trolled release solid dispersions (CRSD), the carrier prop-
erties such as solubility, viscosity, gel-forming ability and
the ratio of drug to carrier are the key factors affecting the
drug dissolution profile. In CRSD, depending on the char-
acteristic of polymers and the miscibility of the drug and
carrier there are two main mechanisms by which the drug
can be released from the system: diffusion and erosion. If the
drugs and polymers are well dispersed in internal structure
of solid dispersions, the diffusion of drugs through the
matrix will be the main mechanism. If the drugs and carriers
exist in separated particles, the solid dispersion erosion may
become the main mechanism for drug release. In some solid
dispersions, both of these mechanisms can control the drug
release at the same time [9].
In this study, imatinib base solid dispersions were for-
mulated with Pluronic F127 by kneading method, and next
XRD, DSC, FTIR, and SEM observations were performed.
In vitro dissolution study was conducted in media at pH 1.2
and pH 6.8. Pluronic F127 has been recently widely used as
wetting and solubilizing agents as well as surface adsorp-
tion excipients. They are employed to enhance the solu-
bility, dissolution, and bioavailability of many hydrophobic
drugs as hydrophilic carrier for its excellent surfactant
properties and oral safety [10]. Based on the results dis-
solution studies of solid dispersions of atorvastatin calcium
with poloxamer 407 conducted in phosphate buffer
(pH 7.4) and water, Nasrin et al. [11] confirm that polymer
might be efficient in formulating both immediate release
and sustained release oral dosage form of drug with
improved dissolution. The higher ratios of poloxamer 407
in solid dispersions allow to sustain the release rate of drug,




Imatinib base (99% purity) synthesized by Silesian Cata-
lysts (Poland), Pluronic F127 were supplied by Sigma-
Aldrich (USA). Concentrated volumetric solution
hydrochloric acid 0.1 mol L-1 was purchased from
Avantor Performance Materials Poland SA (Poland).
Ethanol HPLC grade were obtained from Avantor Perfor-
mance Materials Poland SA (Poland), acetonitrile HPLC
grade were obtained from JT Baker (USA), and potassium
dihydrogen phosphate and 0.05% tetrabutylammonium












Fig. 1 Chemical structure of imatinib base
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Preparation of solid dispersion
Suitable amounts of IMA and PLU were weighed and mixed
in agate mortar with addition of sufficient volume of ethanol
to get the consistency like a slurry. The solvent was then
completely evaporated at 40–45 C with continuous stirring
to obtain dry mass. Afterwards dry mass was triturated in an
agate mortar and sieved through a sieve with a mesh size of
315 lm. The pulverized solid dispersions were stored in a
desiccator at room temperature until use. The mass ratios of
the IMA/PLU mixtures were: 90/10, 80/20, 70/30, 60/30,
50/50, 40/60, 30/70, 20/80, and 10/90%, respectively.
Drug content
Equivalent weight of solid dispersions containing 10 mg of
imatinib were weighed accurately and dissolved in 50 mL
of acetonitrile. The solution was filtered and IMA content
was analysed.
Differential scanning calorimetry (DSC)
The heat flux type calorimeter DSC 214 Polyma (Netzsch,
Germany) was used to obtain DSC curves of pure com-
ponents and solid dispersions. The measurements and data
analysis were carried out using Proteus software (Netzsch,
Germany). Calibration of DSC instrument was performed
using the solid–solid transition temperature of adamantane
(-64.5 C), and melting points of indium (156.6 C), tin
(231.9 C), bismuth (271.4 C), and zinc (419.5 C) as a
standards [12, 13]. About 4–5 mg of each sample was
placed and sealed in 40-lL standard aluminium crucible
with a pierced lid. The same type of empty crucible was
used as a reference.
The DSC scans of all prepared samples were run in
triplicate using dry nitrogen (99.999% purity) as a purge
gas at a flow rate of 50 cm3 min-1. The samples were
heated in the temperature range of 25–250 C at a heating
rate of 10 C min-1.
Powder X-ray diffraction analysis (XRPD)
Powder X-ray diffraction patterns were recorded on a D2
Phaser powder diffractometer (Bruker, Germany) with
CuKa radiation with LynxEye detector. The degree of
diffractions was measured at 15 min-1 between 5 and
60 (2h) with an accuracy of 0.02 throughout the mea-
surement range, at 0.5 s step-1.
Fourier transform infrared (FTIR) spectroscopy
FTIR spectra were registered by using Nicolet 380 spec-
trometer (Thermo Scientific). Samples were mixed with
potassium bromide (KBr) and compressed into a disc using
the Specac hydraulic press (Mettler Toledo, Switzerland)
before scanning from 4000 to 450 cm-1.
Scanning electron microscopy (SEM)
The samples were covered with gold and palladium (60:40;
sputter current 40 mA; sputter time 50 s) using a Quorum
machine (Quorum International, USA) and examined under
a Zeiss EVO MA25 scanning electron microscope.
Intrinsic dissolution rate (IDR) studies
Dissolution tests were carried out under sink conditions in
the two different media: 1000 mL of 0.1 M HCL and
1000 mL of phosphate buffer pH 6.8 at 37 ± 0.5 C and
rotational speeds of 50 rpm. The dissolution system was
fitted with SR8-PLUS (Hanson) and 7-channel peristaltic
pump. IMA (100.0 mg) or an equivalent amount of solid
dispersion discs were prepared compressing powder in
hydraulic press (Specac, Mettler Toledo) for 1 min under 2
t compression force, using a 13-mm punch. Samples were
withdrawn at appropriate time intervals. Quantitative
determination for IMA was performed with HPLC system
(System GOLD 126, Beckman Coulter) with a UV–VIS
detector. The analysis was conducted using Zorbax SB-C8
column (250 9 4.6 mm, 5 lm, Agilent). Analysis was
performed by gradient elution with mixture of acetonitrile
and 0,02 M potassium dihydrogen phosphate (KH2PO4)
with 0.05% tetrabutylammonium hydrogen sulphate solu-
tion with a steady flow rate of 1 mL min-1. Substances
eluted from the column were identified by UV–visible
detector at 236 nm. External standards of IMA were used
to obtain calibration curves. Linear calibration curves for
IMA in 0.1 M HCl solution and in phosphate buffer pH 6.8
were obtained in the range of 2.5–120 lg mL-1 (linearity




The imatinib base content of the formulations was found to
be in the range of 98.22–103.28% of the declared amount.
Table 1 lists results from studies of drug content in solid
dispersions.
Differential scanning calorimetry study
Figure 2 presents heating curves for all the samples per-
formed at a rate of 10 C min-1.
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Melting points of the pure IMA and pure PLU were
found to be 209.7 and 55.8 C, respectively. All of the
DSC curves recorded for solid dispersions show two
endothermal effects, first with the onset at the invariant
temperature (onset at 52.5 C) and second corresponding to
the completely melting of appropriate sample. It indicates
the formation of eutectic mixture between IMA and PLU.
Figure 3 shows the phase diagram of IMA/PLU con-
structed on the basis of the DSC results. The eutectic point
composition was determined by Tamman’s triangle con-
struction [14]. Figure 4 presents the values of the eutectic
melting enthalpy DH (J g-1) for a given dispersions versus
mass ratio of IMA. The values of the eutectic melting
enthalpy DH (Fig. 4, filled circles) go to zero for a com-
position corresponding to pure IMA, indicating no forma-
tion of a terminal solid solution. The characteristic
overlapping of eutectic and liquidus events into a single
peak can be observed on the DSC curves near the eutectic
point. For this reason, the eutectic composition was
Table 1 Imatinib base content in prepared solid dispersions
Formulation code Average content of IMA/%
10/90 IMA/PLU 102.95 ± 0.12
20/80 IMA/PLU 98.70 ± 0.23
30/70 IMA/PLU 102.44 ± 0.10
40/60 IMA/PLU 102.30 ± 0.14
50/50 IMA/PLU 100.78 ± 0.21
60/40 IMA/PLU 103.28 ± 0.34
70/30 IMA/PLU 98.22 ± 0.08
80/20 IMA/PLU 103.39 ± 0.15
90/10 IMA/PLU 101.17 ± 0.22






























Fig. 2 DSC curves of pure
PLU (k), pure IMA (a) and
obtained IMA/PLU solid
dispersions: 90/10% w/w IMA/
PLU (b), 80/20% w/w IMA/
PLU (c), 70/30% w/w IMA/
PLU (d), 60/40% w/w IMA/
PLU (e), 50/50% w/w IMA/
PLU (f), 40/60% w/w IMA/PLU
(g), 30/70% w/w IMA/PLU (h),
20/80% w/w IMA/PLU (i),
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Fig. 3 Phase equilibrium diagram of the IMA–PLU system
IMA/%w/w
















Fig. 4 Eutectic melting enthalpy DH at 52.5 C (filled circles a) and
non-eutectic melting enthalpy (open circles) versus mass ratio of IMA
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determined by plotting the non-eutectic melting enthalpy of
IMA (Fig. 4, open circles) as a function of the mass ratio of
IMA and extrapolating the fitted line to value of zero. The
parameters of the eutectic point have been established as
follows:
• Eutectic composition: mass fraction of IMA 2.3%,
mass fraction of PLU 97.7%;
• Eutectic temperature: 52.5 C.
X-ray diffraction
The X-ray diffraction patterns of IMA, PLU, and solid
dispersions are presented in Fig. 5. This crystalline ima-
tinib base were characterized pattern with peaks at about
5.88, 9.34, 11.85, 12.65, 13.89, 14.96, 15.71, 17.75, 18.48,
19.59, 20.75, 23.98, 24.95, and 28.11 (2h). The X-ray
diffractograms of pure PLU showed the distinct peaks at
18.89 band 23.09. These data reveal that the typical drug
crystalline peaks were still detectable (with reduced
intensity and less number) in the solid dispersion, sug-
gesting a simple mixing of drugs and carriers.
Fourier transform infrared spectroscopy
Figure 6 presents FTIR spectra of Pluronic F127, imatinib
and its solid dispersions. The spectra of pure drug shows
characteristic peak at 3279 cm-1, at 2795 cm-1, at
1646 cm-1, at 1575 cm-1, at 1531 cm-1, at 1453 cm-1, at
1291 cm-1, at 1165 cm-1, at 1110 cm-1, at 926 cm-1, at
858 cm-1, at 796 cm-1, at 703 cm-1, at 647 cm-1 [15].
FTIR spectrum of poloxamer 407 is characterized by
principal absorption peaks at 2882 cm-1 (C–H stretch
aliphatic), 1343 cm-1 (in-plane O–H bend) and 1100 cm-1
(C–O stretch), which were consistent in all binary systems
with the drug. This indicates the absence of drug–excipient
interactions, as all the specific peaks of drug were present
in the solid dispersion.
Scanning electron microscopy (SEM)
SEM photomicrographs (in 3009 magnifications) of pure
IMA, PLU, and obtained solid dispersions are shown in
Fig. 7. From the photomicrograph of pure drug IMA, it is
clear that the drug was present as irregular shaped crystals,




















Fig. 5 XRPD patterns of IMA (a), 90/10% w/w IMA/PLU (b),
80/20% w/w IMA/PLU (c), 70/30% w/w IMA/PLU (d), 60/40% w/w
IMA/PLU (e), 50/50% w/w IMA/PLU (f), 40/60% w/w IMA/PLU (g),
30/70% w/w IMA/PLU (h), 20/80% w/w IMA/PLU (i), 10/90% w/w
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Fig. 6 FTIR spectra of: PLU (a), 90/10% w/w PLU/IMA (b), 80/20%
w/w PLU/IMA (c), 70/30% w/w PLU/IMA (d), 60/40% w/w PLU/
IMA (e), 50/50% w/w PLU/IMA (f), 40/60% w/w PLU/IMA (g),
30/70% w/w PLU/IMA (h), 20/80% w/w PLU/IMA (i), 10/90% w/w
PLU/IMA (j), IMA (k)
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whereas poloxamer 407 was characterized by spherical
particles with very smooth surface. The SEM photomi-
crographs of obtained solid dispersions showed crystalline
homogeneous mixture of drug particles dispersed in the
polymer carrier. Microcrystalline character of drug parti-
cles has demonstrated also by method of XRPD.
Intrinsic dissolution rate (IDR) studies
IDR determination is used inter alia to investigation of
mass transfer phenomena during the dissolution process,
determination of pH–dissolution rate profiles, effect of pH
on the solubilization of poorly soluble drugs, and under-
standing of the relationship between the dissolution rate
and crystalline form [16]. Intrinsic dissolution rate is
defined as the dissolution rate of a pure compound under
the condition of constant surface area. IDR was determined









is the maximum slope in the dissolution curve
evaluated at the start of the dissolution process, A is the
area of the drug disc (cm2), m is the mass (mg), t is the time
(min). The determination of the dissolution rate in com-
parison with solubility studies does not depend on satura-
tion concentration of API in the medium; it is less sensitive
to the errors related to possible phase changes within the
formulation. IDR at pH 1.2 of pure IMA, its solid
dispersions with PLU, and the linear relationship between
the amount of the dissolved drug and time are given in
Table 2. Results suggest that the dissolution rate of IMA
from solid dispersions containing PLU is lower than that of
the pure substance. After 45 min of testing, depending on
the formulation composition, the IDR decreased by half for
the 90/10 IMA/PLU composition and by more than 20-fold
for the 10/90 IMA/PLU % w/w formulations. These results
correspond to a dissolved amount of 47.25 and 3.43% of
the total active pharmaceutical ingredient (API) for the
90/10 and 10/90 IMA/PLU % w/w formulations, respec-
tively. In this time, 86.27% of the pure IMA was dissolved.
Fig. 7 SEM photomicrographs
of: IMA (a), PLU (b), 20/80
IMA/PLU (c) and 70/30 IMA/
PLU (d)
Table 2 Intrinsic dissolution rate (IDR) at pH 1.2 of pure imatinib
base and prepared solid dispersions, and corresponding ratios
Formulation code IDR/mg cm2 min-1 r2
10/90 IMA/PLU 0.168 ± 0.022 0.9601
20/80 IMA/PLU 0.291 ± 0.037 0.9948
30/70 IMA/PLU 0.425 ± 0.065 0.9915
40/60 IMA/PLU 0.786 ± 0.034 0.9990
50/50 IMA/PLU 1.589 ± 0.079 0.9985
60/40 IMA/PLU 1.381 ± 0.081 0.9897
70/30 IMA/PLU 1.651 ± 0.104 0.9839
80/20 IMA/PLU 1.732 ± 0.054 0.9662
90/10 IMA/PLU 1.919 ± 0.033 0.9805
Pure IMA 3.704 ± 0.025 0.9997
Data are expressed as mean ± SD (n = 3)
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As the polymer concentration increases, the dissolution
decreases due to water penetration, the polymer relaxation,
and the forming a viscous gel layer. This layer controls and
retards the release of drug, and the effect depends on the
polymer content in solid dispersion. Figure 8 shows the
dissolution profiles of IMA from solid dispersions within
120 min. A dissolution profile plateau at pH 1.2 was
observed after 55 min of dissolution tests for pure drug.
This plateau corresponds to 100% of dissolved IMA.
Dissolution profiles of pure IMA, and its solid disper-
sions with PLU over a period of 120 min at phosphate
buffer pH 6.8 are shown in Fig. 9. At this time, the pure
IMA was not dissolved in buffer at pH 6.8, and means the
amount of drug in the collected samples, was below
detectable concentration by HPLC method. Solid disper-
sions of IMA with PLU significantly enhanced the disso-
lution rate of IMA within 120 min as compared to pure
IMA. The highest improvement was observed in solid
dispersions containing 20 and 30% w/w polymer.
Conclusions
In the literature, many studies reported for the preparation
of controlled release system using solid dispersion tech-

































Fig. 8 Dissolved amount of
IMA from IMA/PLU solid
dispersions within 120 min of



























Fig. 9 Dissolved amount of
IMA from IMA/PLU solid
dispersions within 120 min of
dissolution process in phosphate
buffer pH 6.8
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hydroxypropylmethylcellulose, poly(ethylene oxide)-car-
boxyvinyl polymer, Eudragit or Kollidon [17]. There are
no data regarding the use of Pluronic F127 to create carrier-
controlled release solid dispersions. Determination of
physicochemical properties and behaviour of drug–poly-
mer solid dispersion in different pH media allow an
assessment of the possibility of their use in oral modified
release dosage forms. Our research has shown that the
dynamics of the release of imatinib base from solid dis-
persions with Pluronic F127 depends on the pH of disso-
lution medium. At pH 1.2, the presence of polymer in solid
dispersion causes delaying of drug release due to formation
a viscous gel layer, whereas at pH 6.8 significant
enhancement of the drug dissolution rate from solid dis-
persions has been observed compared to pure IMA. The
highest improvement was observed in solid dispersions
containing 20 and 30% w/w polymer. Based on DSC
results, it has been found that IMA and PLU form a simple
eutectic system containing 2.3% w/w of IMA at the
eutectic point. Establishing previously unknown IMA/PLU
phase diagram can prove relevant for the formulation of
oral modified release dosage forms. The present investi-
gation confirmed that the hydrophilic polymer Pluronic
F127 could be applied as a suitable matrix to design con-
trolled release formulations of imatinib base. The carrier-
controlled release solid dispersions can deliver an adequate
amount of drug for an extended period of time and thus
offer many advantages such as improved patient compli-
ance due to reduced dosing frequency, decreased side
effects, more constant or prolonged therapeutic effect for
poorly water-soluble drugs.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Sweetman SC, editor. Martindale: the complete drug reference.
36th ed. London: The Pharmaceutical Press; 2009.
2. Bellur Atici E, Karlıg˘a B. Quantitative determination of two
polymorphic forms of imatinib mesylate in a drug substance and
tablet formulation by X-ray powder diffraction, differential
scanning calorimetry and attenuated total reflectance Fourier
transform infrared spectroscopy. J Pharm Biomed Anal.
2015;114:330–40.
3. Mucha I, Baranowski P, Owczarek A, Gajda M, Pluta J, Go´rniak
A, Niklewicz P, Karolewicz B. Thermal stability and decompo-
sitions kinetics under non-isothermal conditions of imatinib
mesylate a form. J Pharm Biomed Anal. 2016;129:9–14.
4. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900
drugs. AAPS J. 2011;13:519–47.
5. Vinod KR, Santosh V, Sandhya S, Otilia BJ, David B, Padmasri
A. A comparative in vitro drug release prospective with two
different polymers for the development of floating single unit
dosage form of imatinib mesylate for chronic myelogenous leu-
kemia. Ars Pharm. 2012;53:1–7.
6. Ravindran VK, Vasa S, Subadhra S, Banji D, Banji O, Rao YM.
Comparative study of mucoadhesive polymers carbopol 974P and
sodium carboxymethyl cellulose for single unit dosage of ima-
tinib mesylate. Malays J Pharm Sci. 2012;1:61–77.
7. Giri TK, Kumar K, Alexander A, Ajazuddin Badwaik H, Tripathi
DK. A novel and alternative approach to controlled release drug
delivery system based on solid dispersion technique. Bull Fac
Pharm (Cairo Univ). 2012;50:147–59.
8. Patil SA, Kuchekar BS, Chabukswar AR, Jagdale SC. Formula-
tion and evaluation of extended-release solid dispersion of met-
formin hydrochloride. J Young Pharm. 2010;2:121–9.
9. Vo CL, Park C, Lee B. Current trends and future perspectives of
solid dispersions containing poorly water-soluble drugs. Eur J
Pharm Biopharm. 2013;85:799–813.
10. Wagh VT, Jagtap VA, Shaikh TJ, Nandedkar SY. Formulation
and evaluation of glimepiride solid dispersion tablets for their
solubility enhancement. J Adv Sci Res. 2012;3:36–41.
11. Nasrin F. Development and in vitro characterization of atorvas-
tatin calcium Poloxamer 407 solid dispersions systems. IJPT.
2014;5:6151–64.
12. van Ekeren PJ, van Genderen ACG, van den Berg GJK. Rede-
termination of the thermodynamic properties of the solid–solid
transition of adamantane by adiabatic calorimetry to investigate
the suitability as a reference material for low-temperature DSC-
calibration. Thermochim Acta. 2006;446:33–5.
13. Della Gatta G, Richardson MJ, Sarge SM, Stolen S. Standards,
calibration and guidelines in microcalorimetry. Part 2. Calibra-
tion standards for differential scanning calorimetry (IUPAC
technical report). Pure Appl Chem. 2006;78:1455–76.
14. Rycerz L. Practical remarks concerning phase diagrams deter-
mination on the basis of differential scanning calorimetry mea-
surements. J Therm Anal Calorim. 2013;113:231–8.
15. Kompella A, Adibhatala KSBR, Rachakonda S, Nannapeneni
VCh. Process for the preparation of highly pure crystalline ima-
tinib base. U.S. Patent US 13/634,725.
16. Yu LX, Carlin AS, Amidon GL, Hussain AS. Feasibility studies
of utilizing disk intrinsic dissolution rate to classify drugs. Int J
Pharm. 2004;270:221–7.
17. Kim HJ, Lee SH, Lim EA, Kim JS. Formulation optimization of
solid dispersion of mosapride hydrochloride. Arch Pharm Sci
Res. 2011;34:1467–75.
B. Karolewicz et al.
123
